Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.

Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).

At Harrow, we’re always interested in connecting with talented, purpose-driven, and mission-minded individuals who share our passion for advancing eye health and improving patients’ lives.

Harrow remains focused on expanding patient access and utilization for IHEEZO and TRIESENCE across Medicare and commercial patient populations. This commitment is …

SAN DIEGO , May 5, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary …

Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more …

The content provided by Harrow on this web site and all site-related services is intended to educate and inform you about Harrow, our product candidates and our technology.

2. Issuer Name and Ticker or Trading Symbol HARROW, INC. [ HROW ] 3. Date of Earliest Transaction (Month/Day/Year) 12/12/2025